Glenmark Pharmaceuticals Monday said it has received tentative nod from the US health regulator for Clobetasol Propionate foam, used to treat inflammation and itching caused by a number of skin conditions like eczema.
Glenmark Pharmaceuticals Inc USA has been granted tentative approval by the United States Food & Drug Administration (US FDA) for Clobetasol Propionate Foam, 0.05 per cent (Emulsion Formulation), the company said in a BSE filing.
The approved product is a generic version of Mylan Pharmaceuticals Inc's Olux-E Foam, 0.05 per cent.
Quoting IQVIA sales data for the 12-month period ended September 2018, Glenmark Pharmaceuticals said, Olux-E Foam achieved annual sales of around USD 13.2 million.
The company's current portfolio consists of 144 products authorised for distribution in the US market and 55 abbreviated new drug applications (ANDAs) pending approval with the USFDA, it added.
Shares of Glenmark Pharmaceuticals were trading 0.06 per cent lower at Rs 637.45 apiece on BSE.
from Daily News & Analysis https://ift.tt/2QiFJYz
We are urgently in need of KlDNEY donors with the sum of $500,000.00 USD (3 crore) and Also In Foreign currency. Apply Now!,For more info Email:
ReplyDeletehealthc976@ gmail.com
Get in touch with a genuine lender. It was amazing how I got the loan. After meeting with (Credit Union Of Dr James Eric) I was able to get my loan, now my business is working well. I want to let you know all this today because it is very fast and 100% reliable. Contact email {financialserviceoffer876@gmail.com} What's-app No: +918929509036
ReplyDeleteGet in touch with a genuine lender. It was amazing how I got the loan. After meeting with (Credit Union Of Dr James Eric) I was able to get my loan, now my business is working well. I want to let you know all this today because it is very fast and 100% reliable. Contact email {financialserviceoffer876@gmail.com} What's-app No: +918929509036
ReplyDelete